Novo Nordisk Stock Slips
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Key Takeaways Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.The committee accused the company of charging "outrageously high prices" for the treatments.
Novo CEO, Sanders to Face Off Over US Prices for Ozempic and Wegovy
In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard Jørgensen will be asked to defend the drugs’ U.S. monthly list prices of $969 and $1,
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions.
Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEO
As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High Prices for Ozempic and Wegovy?
Novo Nordisk CEO heads to Capitol Hill to defend GLP-1 prices
CEO Lars Fruergaard Jørgensen will face questioning from the Senate Committee on Health, Education, Labor, and Pensions about the cost of its GLP-1 drugs, Wegovy and Ozempic.  Health Care Reporter Anjalee Khemlani gives a preview of what investors can expect.
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first cycle of negotiations.
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster weight loss than Wegovy in early clinical trials, according to data presented Wednesday at the European Association for the Study of Diabetes.
Novo Nordisk faces US Senate committee grilling over price of weight loss drugs
was $468 now $279 for your first year. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Offer available here until 24th October.
Senate HELP Committee hearing could get heated as Novo Nordisk CEO testifies
Novo Nordisk CEO faces Senate showdown over high prices for diabetes and weight loss drugs Ozempic and Wegovy.
$50 Billion in Sales Make Ozempic and Wegovy Prices Tougher to Justify
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Ozempic and Wegovy Sales Will Soon Pay for $68 Billion of Novo R&D
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics
Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...